

Table 4.25

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	430,905	99.5%	341,837	99.5%	49,429	99.3%	33,319	99.3%	1,551	99.3%	46,768	99.2%
Epidermoid carcinoma ^d (8051-8131)	215	0.0%	175	0.1%	30	0.1%	-	-	-	-	23	0.0%
Adenocarcinoma ^e	423,201	97.7%	336,133	97.8%	48,041	96.5%	32,837	97.9%	1,521	97.4%	45,815	97.2%
Adenocarcinoma, NOS (8140)	2,726	0.6%	2,117	0.6%	374	0.8%	176	0.5%	16	1.0%	291	0.6%
Infiltrating duct carcinoma (8500)	313,957	72.5%	246,455	71.7%	36,926	74.2%	25,918	77.3%	1,187	76.0%	34,906	74.0%
Lobular carcinoma, NOS (8520)	42,159	9.7%	35,813	10.4%	3,735	7.5%	2,064	6.2%	128	8.2%	3,709	7.9%
Inflammatory adenocarcinoma (8530)	947	0.2%	739	0.2%	143	0.3%	53	0.2%	-	-	166	0.4%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	42,471	9.8%	34,812	10.1%	4,223	8.5%	2,855	8.5%	117	7.5%	4,607	9.8%
Mucinous adenocarcinoma (8480,8482)	8,042	1.9%	6,108	1.8%	1,031	2.1%	801	2.4%	23	1.5%	852	1.8%
Mucin-producing adenocarcinoma (8481)	77	0.0%	59	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	2,213	0.5%	1,963	0.6%	140	0.3%	78	0.2%	-	-	151	0.3%
Papillary adenocarcinoma (8050,8260,8503,8504)	3,197	0.7%	2,307	0.7%	501	1.0%	310	0.9%	-	-	365	0.8%
Paget disease (8540-8543)	1,391	0.3%	1,126	0.3%	146	0.3%	92	0.3%	-	-	130	0.3%
Other adenocarcinomas ^f	6,021	1.4%	4,634	1.3%	810	1.6%	485	1.4%	18	1.2%	630	1.3%
Other specific carcinomas ^g	3,304	0.8%	2,432	0.7%	619	1.2%	220	0.7%	-	-	420	0.9%
Medullary adenocarcinoma (8510-8513)	745	0.2%	498	0.1%	191	0.4%	50	0.1%	-	-	150	0.3%
Other ^h	2,559	0.6%	1,934	0.6%	428	0.9%	170	0.5%	-	-	270	0.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	4,185	1.0%	3,097	0.9%	739	1.5%	253	0.8%	19	1.2%	510	1.1%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

ⁱ Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	443	0.1%	342	0.1%	66	0.1%	31	0.1%	-	-	55	0.1%
Hemangiosarcomas (9120-9126,9170)	250	0.1%	213	0.1%	25	0.1%	-	-	-	-	24	0.1%
Other sarcomas ^d	193	0.0%	129	0.0%	41	0.1%	19	0.1%	-	-	31	0.1%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	942	0.2%	647	0.2%	128	0.3%	136	0.4%	-	-	194	0.4%
Phyllodes tumor, malignant (9020)	810	0.2%	551	0.2%	102	0.2%	127	0.4%	-	-	177	0.4%
Other ^e	132	0.0%	96	0.0%	26	0.1%	-	-	-	-	17	0.0%
Unspecified (8000-8005)	986	0.2%	713	0.2%	151	0.3%	60	0.2%	-	-	132	0.3%
Total ^f	433,276	100.0%	343,539	100.0%	49,774	100.0%	33,546	100.0%	1,562	100.0%	47,149	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	111,997	99.9%	85,458	99.9%	13,652	99.9%	10,843	99.9%	345	99.7%	12,322	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	91,147	81.3%	68,476	80.1%	11,616	85.0%	9,542	87.9%	306	88.4%	10,110	81.9%
Cribriform carcinoma <i>in situ</i> (8201/2)	9,938	8.9%	7,393	8.6%	1,262	9.2%	1,111	10.2%	25	7.2%	1,076	8.7%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	8,013	7.1%	6,193	7.2%	870	6.4%	832	7.7%	27	7.8%	766	6.2%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	25,679	22.9%	19,643	23.0%	3,129	22.9%	2,396	22.1%	108	31.2%	2,820	22.9%
Comedocarcinoma <i>in situ</i> (8501/2)	8,359	7.5%	6,352	7.4%	954	7.0%	931	8.6%	32	9.2%	910	7.4%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,563	1.4%	1,034	1.2%	323	2.4%	171	1.6%	-	-	204	1.7%
Noninfiltrating intracystic carcinoma(8504/2)	317	0.3%	210	0.2%	51	0.4%	52	0.5%	-	-	36	0.3%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,555	1.4%	1,187	1.4%	221	1.6%	125	1.2%	-	-	167	1.4%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	35,468	31.6%	26,282	30.7%	4,786	35.0%	3,875	35.7%	106	30.6%	4,105	33.3%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	16,547	14.8%	13,567	15.9%	1,538	11.3%	970	8.9%	34	9.8%	1,777	14.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	16,531	14.7%	13,558	15.9%	1,533	11.2%	969	8.9%	33	9.5%	1,775	14.4%
Lobular CIS ^f with other CIS ^f (8524/2)	16	0.0%	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	3,633	3.2%	2,929	3.4%	408	3.0%	250	2.3%	-	-	353	2.9%
Other adenocarcinomas ^g	661	0.6%	480	0.6%	89	0.7%	79	0.7%	-	-	82	0.7%
Other <i>in situ</i> histologies ^h	115	0.1%	80	0.1%	-	-	-	-	-	-	16	0.1%
Total	112,112	100.0%	85,538	100.0%	13,667	100.0%	10,854	100.0%	346	100.0%	12,338	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	21,655	97.7%	15,729	97.9%	3,285	96.4%	2,076	98.4%	153	97.5%	4,791	98.1%
Epidermoid carcinoma ^d (8050-8131)	14,299	64.5%	10,041	62.5%	2,507	73.5%	1,364	64.7%	111	70.7%	3,220	65.9%
Squamous cell carcinoma (8070)	10,401	46.9%	7,260	45.2%	1,863	54.6%	990	46.9%	89	56.7%	2,230	45.7%
Squamous cell, keratinizing (8071)	1,393	6.3%	965	6.0%	279	8.2%	120	5.7%	-	-	340	7.0%
Squamous cell, non-keratinizing (8072)	1,783	8.0%	1,318	8.2%	247	7.2%	176	8.3%	-	-	479	9.8%
Squamous cell, Microinvasive (8076)	359	1.6%	255	1.6%	53	1.6%	32	1.5%	-	-	81	1.7%
Other (8050-8069, 8073-8075,8077-8131)	363	1.6%	243	1.5%	65	1.9%	46	2.2%	-	-	90	1.8%
Adenocarcinoma ^e	6,402	28.9%	5,045	31.4%	592	17.4%	610	28.9%	38	24.2%	1,384	28.3%
Adenocarcinoma, NOS (8140)	3,250	14.7%	2,574	16.0%	286	8.4%	306	14.5%	17	10.8%	690	14.1%
Adenosquamous (8560,8570)	707	3.2%	513	3.2%	94	2.8%	90	4.3%	-	-	179	3.7%
Other adenocarcinomas ^f	2,445	11.0%	1,958	12.2%	212	6.2%	214	10.1%	-	-	515	10.5%
Other specific carcinomas ^g	431	1.9%	288	1.8%	87	2.6%	48	2.3%	-	-	79	1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	523	2.4%	355	2.2%	99	2.9%	54	2.6%	-	-	108	2.2%
Sarcoma ^h	103	0.5%	64	0.4%	30	0.9%	-	-	-	-	20	0.4%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	256	1.2%	165	1.0%	58	1.7%	22	1.0%	-	-	38	0.8%
Unspecified (8000-8005)	153	0.7%	105	0.7%	36	1.1%	-	-	-	-	35	0.7%
Total	22,167	100.0%	16,063	100.0%	3,409	100.0%	2,109	100.0%	157	100.0%	4,884	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.
^h Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	240,422	99.4%	187,663	99.5%	29,963	99.3%	18,403	99.4%	1,270	99.0%	27,121	99.3%
Epidermoid carcinoma ^d (8051-8131)	1,604	0.7%	1,362	0.7%	178	0.6%	22	0.1%	-	-	173	0.6%
Squamous cell carcinoma (8070-8078,8083-8084)	1,564	0.6%	1,334	0.7%	173	0.6%	21	0.1%	-	-	167	0.6%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	221,368	91.5%	174,331	92.4%	26,639	88.3%	16,885	91.2%	1,168	91.0%	24,629	90.2%
Adenocarcinoma, NOS (8140)	152,017	62.9%	119,467	63.3%	18,314	60.7%	12,094	65.3%	837	65.2%	17,145	62.8%
Adenocarcinoma in adenomatous polyp (8210)	21,785	9.0%	17,054	9.0%	2,493	8.3%	1,699	9.2%	129	10.1%	2,008	7.4%
Adenocarcinoma in villous adenoma (8261)	4,010	1.7%	3,269	1.7%	430	1.4%	263	1.4%	-	-	498	1.8%
Mucinous adenocarcinoma (8470-8473,8480,8482)	15,202	6.3%	12,383	6.6%	1,668	5.5%	982	5.3%	47	3.7%	1,891	6.9%
Mucin-producing adenocarcinoma (8481)	1,415	0.6%	1,109	0.6%	215	0.7%	77	0.4%	-	-	177	0.6%
Signet ring adenocarcinoma (8490)	2,770	1.1%	2,262	1.2%	304	1.0%	174	0.9%	-	-	339	1.2%
Other adenocarcinomas ^e	24,169	10.0%	18,787	10.0%	3,215	10.7%	1,596	8.6%	126	9.8%	2,571	9.4%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	15,618	6.5%	10,564	5.6%	2,878	9.5%	1,378	7.4%	79	6.2%	2,095	7.7%
Neuroendocrine carcinoid (8240-8245)	11,866	4.9%	7,771	4.1%	2,304	7.6%	1,101	5.9%	69	5.4%	1,695	6.2%
Other ^f	3,752	1.6%	2,793	1.5%	574	1.9%	277	1.5%	-	-	400	1.5%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,832	0.8%	1,406	0.7%	268	0.9%	118	0.6%	-	-	224	0.8%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	163	0.1%	125	0.1%	23	0.1%	-	-	-	-	21	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	431	0.2%	301	0.2%	68	0.2%	55	0.3%	-	-	48	0.2%
Unspecified (8000-8005)	785	0.3%	596	0.3%	112	0.4%	52	0.3%	-	-	111	0.4%
Total ^d	241,801	100.0%	188,685	100.0%	30,166	100.0%	18,521	100.0%	1,283	100.0%	27,301	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	27,121	99.2%	23,055	99.3%	2,597	99.1%	1,191	98.6%	121	99.2%	2,046	99.0%
Epidermoid carcinoma ^d (8051-8131)	8,574	31.4%	5,651	24.3%	1,997	76.2%	834	69.0%	43	35.2%	806	39.0%
Squamous cell carcinoma (8070-8078, 8083-8084)	8,550	31.3%	5,640	24.3%	1,987	75.8%	832	68.9%	43	35.2%	806	39.0%
Adenocarcinoma ^e	17,529	64.1%	16,529	71.2%	514	19.6%	315	26.1%	75	61.5%	1,155	55.9%
Other specific carcinomas ^f	407	1.5%	341	1.5%	34	1.3%	25	2.1%	-	-	32	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	611	2.2%	534	2.3%	52	2.0%	17	1.4%	-	-	53	2.6%
Other specific types ^g	101	0.4%	73	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	118	0.4%	100	0.4%	-	-	-	-	-	-	-	-
Total	27,340	100.0%	23,228	100.0%	2,621	100.0%	1,208	100.0%	122	100.0%	2,067	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^g Other specific types includes sarcomas and other soft tissue tumors.

^g Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	33,854	97.5%	24,289	97.5%	4,588	97.7%	4,393	97.5%	271	97.1%	5,736	96.6%
Hepatocellular carcinoma ^d (8170-8175)	24,309	70.0%	16,782	67.3%	3,629	77.2%	3,433	76.2%	218	78.1%	4,297	72.4%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	8,267	23.8%	6,599	26.5%	760	16.2%	809	18.0%	44	15.8%	1,230	20.7%
Other carcinoma ^e	1,268	3.7%	903	3.6%	199	4.2%	146	3.2%	-	-	208	3.5%
Other specific carcinoma ^f	888	2.6%	641	2.6%	130	2.8%	104	2.3%	-	-	144	2.4%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	380	1.1%	262	1.1%	69	1.5%	42	0.9%	-	-	64	1.1%
Hepatoblastoma (8970)	321	0.9%	224	0.9%	45	1.0%	42	0.9%	-	-	90	1.5%
Sarcoma ^g	295	0.8%	223	0.9%	28	0.6%	41	0.9%	-	-	46	0.8%
Hemangiosarcoma (9120)	132	0.4%	99	0.4%	-	-	23	0.5%	-	-	20	0.3%
Other sarcomas ^h	163	0.5%	124	0.5%	19	0.4%	18	0.4%	-	-	26	0.4%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	54	0.2%	37	0.1%	-	-	-	-	-	-	16	0.3%
Unspecified (8000-8004)	195	0.6%	141	0.6%	26	0.6%	24	0.5%	-	-	45	0.8%
Total ^d	34,726	100.0%	24,919	100.0%	4,698	100.0%	4,506	100.0%	279	100.0%	5,935	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^e Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^f Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

^h Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	48.5	316,080	99.7%	260,060	99.7%	34,701	99.8%	18,892	99.8%	1,034	99.9%	19,066	99.6%
Small cell (8002,8041-8045)	6.0	39,940	12.6%	34,975	13.4%	3,370	9.7%	1,314	6.9%	155	15.0%	2,003	10.5%
Non-small cell	41.0	266,983	84.3%	217,675	83.5%	30,163	86.7%	17,090	90.2%	838	81.0%	16,430	85.8%
Squamous and transitional cell ^d	11.2	71,874	22.7%	60,221	23.1%	8,268	23.8%	2,806	14.8%	306	29.6%	3,670	19.2%
Adenocarcinoma ^e	24.1	157,488	49.7%	126,234	48.4%	17,558	50.5%	12,531	66.2%	417	40.3%	10,141	53.0%
Large cell ^f	0.7	4,384	1.4%	3,589	1.4%	600	1.7%	173	0.9%	-	-	231	1.2%
Non-small cell carcinoma ^g	2.5	16,061	5.1%	12,974	5.0%	2,098	6.0%	847	4.5%	67	6.5%	1,028	5.4%
Other specified carcinomas ^h	2.7	17,176	5.4%	14,657	5.6%	1,639	4.7%	733	3.9%	40	3.9%	1,360	7.1%
Carcinoma, NOS ⁱ	1.4	9,157	2.9%	7,410	2.8%	1,168	3.4%	488	2.6%	41	4.0%	633	3.3%
Sarcoma ^j	0.1	522	0.2%	436	0.2%	49	0.1%	30	0.2%	-	-	64	0.3%
Other specified types ^k	0.0	279	0.1%	225	0.1%	36	0.1%	17	0.1%	-	-	21	0.1%
Total	48.6	316,881	100.0%	260,721	100.0%	34,786	100.0%	18,939	100.0%	1,035	100.0%	19,151	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^f Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^g Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^h Non-small cell carcinoma includes histology 8046.

ⁱ Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

^j Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^k Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Males by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	55.3	161,224	99.7%	130,797	99.7%	18,698	99.7%	10,516	99.7%	492	99.8%	9,801	99.5%
Small cell (8002,8041-8045)	6.5	19,495	12.1%	16,754	12.8%	1,665	8.9%	931	8.8%	71	14.4%	1,032	10.5%
Non-small cell	47.0	136,635	84.5%	110,002	83.9%	16,327	87.1%	9,287	88.1%	398	80.7%	8,409	85.4%
Squamous and transitional cell ^d	15.3	44,154	27.3%	36,644	27.9%	5,080	27.1%	2,074	19.7%	174	35.3%	2,272	23.1%
Adenocarcinoma ^e	25.1	73,378	45.4%	57,902	44.1%	8,854	47.2%	6,129	58.1%	161	32.7%	4,845	49.2%
Large cell ^f	0.8	2,463	1.5%	1,979	1.5%	355	1.9%	116	1.1%	-	-	141	1.4%
Non-small cell carcinoma ^g	3.1	9,059	5.6%	7,150	5.5%	1,271	6.8%	560	5.3%	39	7.9%	572	5.8%
Other specified carcinomas ^h	2.6	7,581	4.7%	6,327	4.8%	767	4.1%	408	3.9%	21	4.3%	579	5.9%
Carcinoma, NOS ⁱ	1.8	5,094	3.2%	4,041	3.1%	706	3.8%	298	2.8%	23	4.7%	360	3.7%
Sarcoma ^j	0.1	321	0.2%	271	0.2%	27	0.1%	19	0.2%	-	-	35	0.4%
Other specified types ^k	0.1	148	0.1%	118	0.1%	20	0.1%	-	-	-	-	-	-
Total	55.4	161,693	100.0%	131,186	100.0%	18,745	100.0%	10,544	100.0%	493	100.0%	9,846	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^f Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^g Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^h Non-small cell carcinoma includes histology 8046.

ⁱ Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

^j Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^k Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	43.4	154,856	99.8%	129,263	99.8%	16,003	99.8%	8,376	99.8%	542	100.0%	9,265	99.6%
Small cell (8002,8041-8045)	5.7	20,445	13.2%	18,221	14.1%	1,705	10.6%	383	4.6%	84	15.5%	971	10.4%
Non-small cell	36.6	130,348	84.0%	107,673	83.1%	13,836	86.3%	7,803	92.9%	440	81.2%	8,021	86.2%
Squamous and transitional cell ^d	7.8	27,720	17.9%	23,577	18.2%	3,188	19.9%	732	8.7%	132	24.4%	1,398	15.0%
Adenocarcinoma ^e	23.5	84,110	54.2%	68,332	52.8%	8,704	54.3%	6,402	76.3%	256	47.2%	5,296	56.9%
Large cell ^f	0.5	1,921	1.2%	1,610	1.2%	245	1.5%	57	0.7%	-	-	90	1.0%
Non-small cell carcinoma ^g	2.0	7,002	4.5%	5,824	4.5%	827	5.2%	287	3.4%	28	5.2%	456	4.9%
Other specified carcinomas ^h	2.7	9,595	6.2%	8,330	6.4%	872	5.4%	325	3.9%	19	3.5%	781	8.4%
Carcinoma, NOS ⁱ	1.1	4,063	2.6%	3,369	2.6%	462	2.9%	190	2.3%	18	3.3%	273	2.9%
Sarcoma ^j	0.1	201	0.1%	165	0.1%	22	0.1%	-	-	-	-	29	0.3%
Other specified types ^k	0.0	131	0.1%	107	0.1%	16	0.1%	-	-	-	-	-	-
Total	43.5	155,188	100.0%	129,535	100.0%	16,041	100.0%	8,395	100.0%	542	100.0%	9,305	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^f Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^g Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^h Non-small cell carcinoma includes histology 8046.

ⁱ Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

^j Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^k Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	63,339	85.4%	3,814	94.3%	22,466	97.7%	1,766	21.6%	3,088	95.8%
Squamous cell carcinoma (8070-8078,8083-8084)	61,917	83.5%	3,608	89.2%	22,108	96.1%	1,685	20.6%	3,055	94.8%
Adenocarcinoma ^c	7,315	9.9%	166	4.1%	277	1.2%	5,108	62.5%	109	3.4%
Other specific carcinomas ^d	673	0.9%	-	-	65	0.3%	414	5.1%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,948	2.6%	-	-	104	0.5%	550	6.7%	-	-
Sarcoma and soft tissue ^e	233	0.3%	-	-	34	0.1%	53	0.6%	-	-
Other specific types ^f	413	0.6%	36	0.9%	-	-	205	2.5%	-	-
Unspecified (8000-8005)	244	0.3%	-	-	42	0.2%	76	0.9%	-	-
Total	74,166	100.0%	4,044	100.0%	23,000	100.0%	8,172	100.0%	3,224	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	8,194	82.7%	2,605	67.2%	16,315	98.3%	3,677	97.3%	1,414	90.0%
Squamous cell carcinoma (8070-8078,8083-8084)	7,805	78.8%	2,454	63.3%	16,150	97.3%	3,648	96.5%	1,404	89.4%
Adenocarcinoma ^c	1,400	14.1%	122	3.1%	86	0.5%	21	0.6%	26	1.7%
Other specific carcinomas ^d	46	0.5%	38	1.0%	47	0.3%	33	0.9%	17	1.1%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	70	0.7%	1,037	26.7%	88	0.5%	23	0.6%	59	3.8%
Sarcoma and soft tissue ^e	46	0.5%	46	1.2%	17	0.1%	17	0.4%	-	-
Other specific types ^f	125	1.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	23	0.2%	16	0.4%	28	0.2%	-	-	42	2.7%
Total	9,905	100.0%	3,878	100.0%	16,592	100.0%	3,780	100.0%	1,571	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	33,619	91.1%	27,373	91.7%	3,040	87.5%	2,770	91.7%	124	84.4%	4,218	87.5%
Epidermoid carcinoma ^d (8051-8131)	209	0.6%	160	0.5%	23	0.7%	26	0.9%	-	-	32	0.7%
Adenocarcinoma ^e	31,075	84.3%	25,474	85.3%	2,631	75.7%	2,575	85.2%	118	80.3%	3,838	79.6%
Adenocarcinoma, NOS (8140)	3,675	10.0%	2,952	9.9%	467	13.4%	216	7.2%	16	10.9%	456	9.5%
Papillary adenocarcinoma, NOS (8050,8260)	273	0.7%	203	0.7%	50	1.4%	19	0.6%	-	-	29	0.6%
Clear cell adenocarcinoma (8310,9110)	2,126	5.8%	1,604	5.4%	116	3.3%	376	12.4%	-	-	251	5.2%
Endometrioid carcinoma (8380-8383,8570)	3,507	9.5%	2,870	9.6%	199	5.7%	387	12.8%	-	-	501	10.4%
Cystadenocarcinoma, NOS (8440,8450)	64	0.2%	55	0.2%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	12,711	34.5%	10,588	35.5%	1,054	30.3%	908	30.1%	53	36.1%	1,406	29.2%
Papillary serous cystadenocarcinoma (8460-8462)	4,776	12.9%	3,987	13.4%	436	12.5%	297	9.8%	19	12.9%	645	13.4%
Mucinous cystadenocarcinoma (8470-8473)	408	1.1%	318	1.1%	36	1.0%	46	1.5%	-	-	60	1.2%
Mucinous adenocarcinoma (8480,8482)	1,582	4.3%	1,272	4.3%	129	3.7%	154	5.1%	-	-	211	4.4%
Mucin-producing adenocarcinoma(8481)	26	0.1%	20	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,927	5.2%	1,605	5.4%	133	3.8%	168	5.6%	-	-	264	5.5%
Other specific carcinomas ^g	941	2.6%	620	2.1%	233	6.7%	63	2.1%	-	-	172	3.6%
Stromal cell tumor (8620-8631,8650)	721	2.0%	460	1.5%	194	5.6%	45	1.5%	-	-	138	2.9%
Other ^h	220	0.6%	160	0.5%	39	1.1%	18	0.6%	-	-	34	0.7%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,394	3.8%	1,119	3.7%	153	4.4%	106	3.5%	-	-	176	3.6%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	111	0.3%	83	0.3%	24	0.7%	-	-	-	-	19	0.4%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	2,773	7.5%	2,133	7.1%	350	10.1%	220	7.3%	17	11.6%	530	11.0%
Mullerian mixed tumor (8950-8951,8980)	1,334	3.6%	1,096	3.7%	146	4.2%	67	2.2%	-	-	151	3.1%
Teratoma, malignant (9080-9085,9102)	560	1.5%	361	1.2%	108	3.1%	66	2.2%	-	-	171	3.5%
Other	879	2.4%	676	2.3%	96	2.8%	87	2.9%	-	-	208	4.3%
Unspecified (8000-8005)	381	1.0%	276	0.9%	61	1.8%	29	1.0%	-	-	56	1.2%
Total ^d	36,884	100.0%	29,865	100.0%	3,475	100.0%	3,021	100.0%	147	100.0%	4,823	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	69,818	98.4%	55,902	98.5%	8,656	98.4%	4,643	98.3%	232	96.7%	7,299	98.2%
Epidermoid carcinoma ^d (8051-8131)	192	0.3%	146	0.3%	26	0.3%	17	0.4%	-	-	21	0.3%
Adenocarcinoma ^e	60,326	85.0%	48,497	85.4%	7,434	84.5%	3,910	82.8%	193	80.4%	6,278	84.4%
Adenocarcinoma, NOS (8140)	47,997	67.7%	38,596	68.0%	6,045	68.7%	2,981	63.1%	153	63.8%	4,890	65.8%
Papillary adenocarcinoma, NOS (8260)	44	0.1%	33	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,567	2.2%	1,272	2.2%	149	1.7%	128	2.7%	-	-	189	2.5%
Mucin-producing adenocarcinoma (8481)	384	0.5%	305	0.5%	54	0.6%	24	0.5%	-	-	39	0.5%
Infiltrating duct carcinoma (8500-8503,8507,8514)	8,238	11.6%	6,606	11.6%	947	10.8%	618	13.1%	24	10.0%	871	11.7%
Other adenocarcinoma ^f	2,096	3.0%	1,685	3.0%	234	2.7%	153	3.2%	-	-	278	3.7%
Other specific carcinomas ^g	6,956	9.8%	5,483	9.7%	844	9.6%	524	11.1%	24	10.0%	738	9.9%
Islet cell carcinoma (8150-8155)	362	0.5%	301	0.5%	41	0.5%	16	0.3%	-	-	30	0.4%
Other carcinomas ^h	6,594	9.3%	5,182	9.1%	803	9.1%	508	10.8%	22	9.2%	708	9.5%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,344	3.3%	1,776	3.1%	352	4.0%	192	4.1%	-	-	262	3.5%
Sarcoma and other soft tissue tumors ⁱ	55	0.1%	45	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	78	0.1%	61	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	979	1.4%	769	1.4%	128	1.5%	70	1.5%	-	-	113	1.5%
Total	70,932	100.0%	56,779	100.0%	8,796	100.0%	4,725	100.0%	240	100.0%	7,436	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	42,127	91.1%	29,986	92.1%	5,701	85.2%	5,657	92.2%	267	96.4%	7,751	94.0%
Epidermoid carcinoma ^d (8051-8131)	383	0.8%	268	0.8%	74	1.1%	36	0.6%	-	-	46	0.6%
Squamous cell carcinoma (8070-8078,8083-8084)	362	0.8%	253	0.8%	71	1.1%	33	0.5%	-	-	40	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	37,148	80.4%	26,311	80.8%	4,950	74.0%	5,283	86.1%	238	85.9%	6,764	82.0%
Adenocarcinoma, NOS (8140)	21,351	46.2%	15,809	48.6%	2,727	40.8%	2,489	40.6%	131	47.3%	3,234	39.2%
Adenocarcinoma, intestinal type (8144)	3,820	8.3%	2,208	6.8%	665	9.9%	883	14.4%	29	10.5%	729	8.8%
Carcinoma, diffuse type (8145)	1,729	3.7%	1,073	3.3%	198	3.0%	426	6.9%	-	-	462	5.6%
Linitus plastica (8142)	194	0.4%	147	0.5%	19	0.3%	25	0.4%	-	-	45	0.5%
Mucinous adenocarcinoma (8470-8473,8480,8482)	535	1.2%	370	1.1%	89	1.3%	65	1.1%	-	-	93	1.1%
Mucin-producing adenocarcinoma (8481)	124	0.3%	88	0.3%	23	0.3%	-	-	-	-	26	0.3%
Signet ring adenocarcinoma (8490)	7,410	16.0%	5,262	16.2%	910	13.6%	1,098	17.9%	57	20.6%	1,800	21.8%
Other adenocarcinomas ^e	1,985	4.3%	1,354	4.2%	319	4.8%	284	4.6%	-	-	375	4.5%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	3,732	8.1%	2,820	8.7%	520	7.8%	228	3.7%	24	8.7%	797	9.7%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	864	1.9%	587	1.8%	157	2.3%	110	1.8%	-	-	144	1.7%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	114	0.2%	94	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	3,763	8.1%	2,324	7.1%	949	14.2%	433	7.1%	-	-	437	5.3%
Unspecified (8000-8005)	220	0.5%	149	0.5%	29	0.4%	35	0.6%	-	-	50	0.6%
Total ^d	46,224	100.0%	32,553	100.0%	6,688	100.0%	6,135	100.0%	277	100.0%	8,250	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	95,523	99.7%	75,992	99.7%	7,059	99.5%	9,777	99.8%	382	100.0%	14,968	99.7%
Epidermoid carcinoma ^d (8051-8131)	104	0.1%	86	0.1%	-	-	-	-	-	-	16	0.1%
Adenocarcinoma ^e	92,750	96.8%	73,769	96.8%	6,785	95.7%	9,554	97.5%	371	97.1%	14,538	96.8%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	86,518	90.3%	68,923	90.5%	6,057	85.4%	9,038	92.2%	351	91.9%	13,725	91.4%
Follicular carcinoma (8330-8332,8335)	4,046	4.2%	3,059	4.0%	526	7.4%	363	3.7%	-	-	550	3.7%
Oxyphilic (8290)	1,741	1.8%	1,421	1.9%	164	2.3%	116	1.2%	-	-	201	1.3%
Other specific carcinomas ^f	1,540	1.6%	1,276	1.7%	133	1.9%	95	1.0%	-	-	245	1.6%
Medullary carcinoma (8510)	1,488	1.6%	1,235	1.6%	130	1.8%	89	0.9%	-	-	239	1.6%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	1,129	1.2%	861	1.1%	133	1.9%	119	1.2%	-	-	169	1.1%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	729	0.8%	577	0.8%	72	1.0%	73	0.7%	-	-	117	0.8%
Sarcoma and other soft tissue tumors ^g	19	0.0%	16	0.0%	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	256	0.3%	181	0.2%	29	0.4%	22	0.2%	-	-	38	0.3%
Total	95,806	100.0%	76,195	100.0%	7,091	100.0%	9,799	100.0%	382	100.0%	15,011	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.